Current treatments for cardiac amyloidosis target the production of precursor proteins by chemotherapy for AL [1, 5], and oligonucleotide gene silencing therapies [6] or targetted protein stabilisers (tafamidis) [7] for ATTR. The gene discussed is TTR; the disease is axial length measurement.